- Home
- FCT vs CNTX Comparison
FCT vs CNTX Comparison
Compare FCT & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCT | CNTX |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.6M | 283.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | FCT | CNTX |
|---|---|---|
| Price | $9.77 | $2.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 102.7K | ★ 881.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 11.29% | N/A |
| EPS Growth | N/A | ★ 69.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.61 | $0.49 |
| 52 Week High | $10.30 | $3.62 |
Technical Indicators
Market Signals| Indicator | FCT | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.18 | 55.31 |
| Support Level | $9.59 | $2.07 |
| Resistance Level | $10.04 | N/A |
| Average True Range (ATR) | 0.08 | 0.30 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 45.65 | 49.68 |
Price Performance
Historical ComparisonAbout FCT First Trust Senior Floating Rate Income Fund II of Beneficial Interest
First Trust Senior Floating Rate Income Fund II is a United States-based diversified, closed-end management investment company. Its investment objective is to seek a high level of current income. As a secondary objective, it attempts to preserve capital. The fund invests in a portfolio of senior secured floating-rate corporate loans (Senior Loans) of companies from different industries, such as Insurance, Software, Health Care Providers and Services, Professional Services, Health Care Technology, IT Services, and others.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.